Clinical Trials Sponsored by Procept

Total 416 results

PROCEPT BioRobotics

Recruiting

PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System

Localized Prostate Cancer

United States
PROCEPT BioRobotics

Recruiting

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Benign Prostatic Hyperplasia | Localized Prostate Cancer

Lebanon, Hong Kong, United States
PROCEPT BioRobotics

Completed

Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II (AHA II)

Benign Prostatic Hyperplasia

India
PROCEPT BioRobotics

Completed

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER) (WATER)

Benign Prostatic Hyperplasia (BPH)

United States, Australia, United Kingdom, New Zealand
PROCEPT BioRobotics

Unknown

UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

United Kingdom
PROCEPT BioRobotics

Completed

Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III (AHAIII)

Benign Prostatic Hyperplasia

India
PROCEPT BioRobotics

Unknown

Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (OPEN WATER)

BPH

Australia, Lebanon, United Kingdom, Germany, New Zealand
PROCEPT BioRobotics

Completed

French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

Benign Prostatic Hyperplasia (BPH)

France
PROCEPT BioRobotics

Completed

Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia (AHA)

Benign Prostatic Hyperplasia

India
PROCEPT BioRobotics

Completed

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II (WATERII)

Benign Prostatic Hyperplasia (BPH)

United States, Canada
PROCEPT BioRobotics

Completed

AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia (ABS)

Benign Prostatic Hyperplasia

India
University of Bonn
PROCEPT BioRobotics

Recruiting

WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia (WATER III)

BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

Germany
Corcept Therapeutics

Completed

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)

Cushing Syndrome

United States, Austria, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain
Corcept Therapeutics

Enrolling by invitation

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Cushing Syndrome

United States, Austria, Bulgaria, Germany, Israel, Italy, Netherlands, Romania, Spain, Poland, Canada
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Healthy

United States
Corcept Therapeutics

Active, not recruiting

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Antipsychotic-induced Weight Gain (AIWG)

United States
Corcept Therapeutics

Completed

This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.

Antipsychotic-induced Weight Gain (AIWG)

United States
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Healthy Adults

United Kingdom
Corcept Therapeutics

Completed

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

Healthy Adults

Netherlands
Corcept Therapeutics

Completed

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Healthy

United States
Corcept Therapeutics

Completed

A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

Healthy

United Kingdom
Corcept Therapeutics

Completed

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Relacorilant Food Effect Study in Healthy Subjects

Healthy | Food-drug Interaction

United States
Corcept Therapeutics

Completed

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Healthy

United States
Corcept Therapeutics

Completed

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Sarcoma | Breast Cancer | Prostatic Neoplasms | Carcinoma, Transitional Cell | Prostate Cancer | Non-small Cell Lung Cancer | Ovarian Epithelial Cancer Recurrent

United States
Corcept Therapeutics

Completed

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Cushing's Syndrome | Cushing's Disease

United States
Corcept Therapeutics

Completed

A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers

Healthy Subjects

United States
Corcept Therapeutics

Completed

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Psychotic Disorders | Major Depressive Disorder

United States
Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Corcept Therapeutics

Active, not recruiting

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (GRADIENT)

Hypercortisolism

United States, Austria, Bulgaria, Germany, Israel, Italy, Poland, Romania, Spain
Corcept Therapeutics

Active, not recruiting

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (DAZALS)

Amyotrophic Lateral Sclerosis

United States, Belgium, Canada, France, Germany, Ireland, Netherlands, Poland, Spain, United Kingdom
Corcept Therapeutics

Terminated

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM)

Cushing's Syndrome
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Corcept Therapeutics

Completed

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Healthy

India
Corcept Therapeutics

Completed

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Cushing's Syndrome

Netherlands, United States, Hungary, Italy, United Kingdom
Corcept Therapeutics

Completed

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Corcept Therapeutics

Completed

First-in-human Study in Healthy Subjects

Healthy

United Kingdom
Corcept Therapeutics

Completed

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Healthy

United States
Corcept Therapeutics

Completed

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Healthy

United States
Corcept Therapeutics

Completed

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

Healthy | Drug Interaction Potentiation

United States

3

Subscribe